2014 turnover growth of 0.2% and volumes of 1.3% compared to 2013. Non-loanable drugs also recorded a decrease of 1.9% in turnover and 2.2% in volumes. On the other hand, generics grew (both in turnover, +7.8%, and in pieces, +6.7%)
February 3, 2015 – PharmaKronos
Crisis or no crisis, the pharmacy channel holds its own and, thanks to substantial stability in terms of turnover and sales volumes, manages to close the 2014 accounts positively, albeit slightly. This is the summary of the analysis conducted New Line Market Research on sales data relating to over 5 thousand pharmacies, which highlights a growth in turnover of 0.2% and sales volumes of 1.3% compared to 2013.
The plus sign, it must be said - Federfarma Lazio points out - is almost exclusively due to the 'commercial' area (Sop, Otc and parapharmaceuticals) which saw an increase in turnover of 2.2%, while the ethical turnover recorded a decrease of 1,1%. Opposite trends in the analysis by volumes, where prescription drugs record the best performance with +1.7% against +0.7% for the commercial ones.
A confirmation of the now consolidated trend of the progressive loss of value of the recipe. In particular, loanable drugs remain 
stable in volumes (+0.8%), while and instead lost -2.5% in turnover, in all probability due to the drop in the price of branded medicines, the result of competitive pressure from generic medicines.
The non-loanable drug also recorded a decrease of 1.9% in turnover and 2.2% in volumes. On the other hand, generics grew (both in turnover, +7.8%, and in pieces, +6.7%), even if the 2014 results were lower than those recorded in the previous two years.
Barbara DiChiara
